Microbiotica Completes Phase 1b Ulcerative Colitis Trial Recruitment
Microbiotica has completed patient enrollment in its Phase 1b COMPOSER-1 trial of MB310, a live biotherapeutic product (LBP) for...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Microbiotica has completed patient enrollment in its Phase 1b COMPOSER-1 trial of MB310, a live biotherapeutic product (LBP) for...
In this interview, we sit down with Jane Myles and Joe Dustin, leaders in clinical operations and digital transformation...
Allogene Therapeutics has discontinued the fludarabine, cyclophosphamide, and ALLO-647 (FCA) arm of its pivotal ALPHA3 study in first-line large...
Artelo Biosciences has received positive scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its...
BioXcel Therapeutics has completed the last patient visit in its pivotal Phase 3 SERENITY At-Home trial of BXCL501 (dexmedetomidine)...
Orchestra BioMed (OBIO) has secured $70 million in new funding from Ligand Pharmaceuticals and existing partner Medtronic, bolstering its...
Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics. The deal brings Sage’s recently approved postpartum depression (PPD) drug,...
Myriad Genetics secured a five-year, $200 million senior secured term loan from OrbiMed, replacing its previous asset-based lending (ABL)...
The FDA has signaled its acceptance of PolTREG’s existing clinical data in Stage 3 Type 1 diabetes (T1D) as...
BriaCell Therapeutics has added UCLA Health Jonsson Comprehensive Cancer Center as a clinical site for its ongoing Phase 3...